Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2002

Keizo Yamaguchi, Yoshikazu Ismi, Morihiro Iwata, Naoki Watanabe, Nobuyuki Uehara, Minoru Yasujima, Takeshi Kasai, Akira Suwabe, Ritsuko Obata, Mitsuo Kaku, Keiji Kanemitsu, Hiroshi Yoshida, Toshio Satoh, Masami Murakami, Ayako Takahashi, Kouichi Itoh, Yasuhiro Shibuya, Harushegi Kanno, Setsuko Kubo, Shigefumi MaesakiGiichi Hashikita, Jun Igari, Toyoko Oguri, Jun Okada, Yoko Tazawa, Hideki Nakashima, Hiromu Takemura, Toshinobu Horii, Hisashi Baba, Shiomi Ishigo, Naohisa Fujita, Tosiiiaki Komori, Satoshi Ichiyama, Shigetaka Maeda, Kiyoharu Yamanaka, Yoko Murata, Masanori Aihara, Shohiro Kinoshita, Tomohiko Taminato, Kiyoshi Negayama, Mitsuharu Murase, Hitoshi Miyamoto, Nobuuchika Kusano, Eiichirou Mihara, Masayum Kambe, Hideyuki Itaha, Junko Ono, Hisae Yoshimura, Yoichi Hirakata, Junichi Matsuda, Tetsunori Saikawa, Kazufumi Hiramatsu

研究成果: Review article査読

4 被引用数 (Scopus)

抄録

The antibacterial activity of meropenem (MEPM) and odler paremeral antibiotics against clinical isolates of 899 strains of Gram-positive bacteria, 1500 strains of Gram-negative bacteria, and 158 strains of anaerobic bacteria obtained from 28 medical institutions during 2002 was measured. The results were as follows; 1. MEPM was more active than other carbapenem antibiotics against Gram-negative bacteria, especially against enterobacteriaceae and Haemophilus influenzae. MIC 90 of MEPM against Pseudomonas aeruginosa was the lowest of the drugs tested. MEPM showed low cross-resistant rate against both imipenem-resistant P. aeruginosa and ciprofloxacin-resistant P. aeruginosa. MEPM was active against most of the species tested in Gram-positive and anaerobic bacteria, except for multi-drug resistant strains including methicillin-resistant Staphylococcus aureus (MRSA), methicillin-resistant Staphylococcus epidermidis (MRSE). 2. The proportion of extended-spectrum β-lactamase (ESBL) strains was 3.1% (4 strains) in Escherichia coli and 1.9% (2 strains) in Klebsiella pneumoniae. Carbapenems including MEPM were active against these ESBL strains. In conclusion, the results from this surveillance study suggest that MEPM retains its potent and broad antibacterial activity and therefore is a clinically useful carbapenem at present, 7 years after available for commercial use.

本文言語English
ページ(範囲)70-104
ページ数35
ジャーナルThe Japanese Journal of Antibiotics
57
1
出版ステータスPublished - 2004 2月
外部発表はい

ASJC Scopus subject areas

  • 微生物学(医療)
  • 薬理学(医学)
  • 感染症

フィンガープリント

「Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2002」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル